Q&A: Professor Ros Eeles
How a genetic test could spot men at risk of developing prostate cancer
Patient and public involvement and engagement (PPI/E)
Involving patients and the public with our research ensures that we focus on the issues that matter most to those affected by cancer.Highlights
Research is key to future treatment
Our six research themes and two cross-cutting themes bring together a critical mass of internationally renowned clinicians, scientists and allied health professionals, allowing us to ensure that novel diagnostics and physical and systemic therapies are rapidly available to all cancer patients.
The BRC Molecular Pathology Starter Programme
Applications are now open for our programme to train the next generation of histopathologists in the latest diagnostic techniques.
Find out more and applyLatest news
News: Radiotherapy can be used in hard-to-treat bladder cancer
A new clinical trial has found that more targeted forms of radiotherapy can effectively treat bladder cancer which has spread to the lymph nodes of the pelvis.
Find out more
News: World-first treatment with ‘acoustic cluster therapy’
The first patient has been treated with an innovative new technology that uses microscopic clusters of bubbles and liquid droplets to enhance the delivery of chemotherapy drugs to tumours.
Find out more
News: Men over 40 with BRCA2 gene fault ‘should get regular PSA screening’
Experts are urging that guidelines should change so that all men over the age of 40 with faults in the BRCA2 gene should be offered regular PSA testing to detect early signs of prostate cancer.
Find out more